Every-day clinical practice in patients with advanced non-small-cell lung cancer

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 273-277

  Zietemann, V ^a   Duell, T ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Oncology Department   (Germany)

Author keywords

First line therapy; Non small cell lung cancer; Observational study; Radiotherapy; Second line therapy; Systemic therapy; Third line therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY; SURVIVAL ANALYSIS;

EID: 77950516513     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.023     Document Type: Article

References (8)

1. Grossi F., Gridelli C., Aita M., De Marinis F. Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. Crit Rev Oncol Hematol 2008, 67:16-26.
2. Vansteenkiste J. Improving patient management in metastatic non-small cell lung cancer. Lung Cancer 2007, 57(SUPP1 1 2):S12-S17.
3. Ramalingam S., Sandler A.B. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 2006, 11:655-665.
4. Kleinbaum D.G., Klein M. Survival analysis-a self-learning text 2005, Springer-Verlag/Business Media, New York. 2nd ed.
5. Stinchcombe T.E., Socinski M.A. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008, 13(Suppl 1):28-36.
6. Okamoto T., Maruyama R., Shoji F., Asoh H., Ikeda J., Miyamoto T., et al. Long-term survivors in stage IV non-small cell lung cancer. Lung Cancer 2005, 47:85-91.
7. Hernan M.A., Brumback B., Robins J.M. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000, 11:561-570.
8. Yamaguchi T., Ohashi Y. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II. An application in a clinical trial of unresectable non-small-cell lung cancer. Stat Med 2004, 23:2005-2022.